Navigation Links
Nutrigenomics - Developing Personalized Diets for Disease Prevention - Is the Focus of a Special Issue of OMICS
Date:12/29/2008

NEW ROCHELLE, N.Y., Dec. 29 /PRNewswire/ -- The emerging field of nutrigenomics, which aims to identify the genetic factors that influence the body's response to diet and studies how the bioactive constituents of food affect gene expression, is explored in a series of provocative, interdisciplinary reports and analyses in the December 2008 Special Issue (Volume 12, number 4) of OMICS: A Journal of Integrative Biology, a peer-reviewed journal published by Mary Ann Liebert, Inc. (www.liebertpub.com). The issue is available free online at www.liebertpub.com/omi

This compendium of papers describing the innovative new area of study encompassed by nutrigenomics research is Part 1 of a two-part series. Part 2 will be published in Spring 2009.

Nutrigenomics' bidirectional approach to investigating how the genetic traits of an individual or population interact with their diet offers many possibilities for targeted clinical interventions and preventive medicine. These may include modifying either diet or the biochemical response to food exposure to prevent disease in individuals shown to be susceptible to the consequences of unfavorable dietary/genomic interactions. In the future, nutrigenomics may potentially help guide the development of customized diets based on an individual's genetic make-up.

"In contrast to previous applications of genomics technologies where the goal is to distinguish existing disease from absence of disease, nutrigenomics aims to discern nuanced differences in predisease states such that personalized dietary interventions can be designed to prevent or modify future disease susceptibility," write Guest Editors Beatrice Godard, PhD, and Vural Ozdemir, MD, PhD, from the Department of Social and Preventive Medicine, University of Montreal, Quebec, Cana
'/>"/>

SOURCE Mary Ann Liebert, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. GlaxoSmithKline and Dynavax Announce Worldwide Strategic Alliance : – Developing First-in-Class Endosomal TLR Inhibitors for Autoimmune and Inflammatory Diseases –
2. MaxCyte Presents a Panel Discussion With Industry Experts on the Challenges in Developing Cell-Based Screening Assays for Drug Discovery - LIVE Q&A to Follow
3. UC San Diego scientists developing brain imaging methods for studying natural human behavior
4. International workshop aims to boost public engagement work in developing countries
5. Frost & Sullivan Honours GELITA for Developing European Health Ingredient of the Year
6. CEO to Address Los Angeles Business Leaders About Developing Pandemic and Business Continuity Plans
7. Chemstar Corporation Responds to Industry Demand by Developing an All-In-One Bodily Fluid Clean-Up Kit
8. International Implementation of Breast Health Guidelines for Developing Countries Published by Cancer
9. Dementia Underestimated in Developing Countries
10. Prevalence of dementia in the developing world underestimated
11. China Medicine Releases White Paper on Developing Recombinant Aflatoxin-Detoxifizyme

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2009)... Pilots will enable local organizations to t...er for consumers who lack access , ...men Fund, a nonprofit venture firm addressing pove...it has selected four organizations in Kenya to con...r transportation and storage. , , ,The pilot progr...
(Date:12/1/2009)..., LONDON, Dec. 1 Lucrative opportu...s patient monitoring devices market, particularly ...his segment is growing at a rapid pace. The primar...s among an ageing population about devices that he...erly prefer to age at home - a trend supported by ...
(Date:12/1/2009)... Dec. 1 /PRNewswire/ - Sentinelle Medical Inc., a ...vanced visualization software, extends its line of...gical Society of North America (RSNA) annual meeti... Hall A). ,, With the unique Vanguard(R) patien...metry(TM), Sentinelle,s line of breast coils are r...
(Date:12/1/2009)... NYC based physician Dr. Michael Aziz announ...;The Perfect 10 Diet: 10 Key Hormones that Hold th..." (Source books Jan. 2110). The book deliver...pular diets disturb hormones, and promises a drama...alancing hormones. , New ...
(Date:12/1/2009)... Amadeus will operate as a division of Xybio...olls, NJ (PRWEB) December 1, 2009 -- Xybion Corpor...quisition of all operating assets of Quebec City b...t of enterprise governance, risk, compliance and q..., a corporate performance management organization ...
Breaking Medicine News(10 mins):Health News:Acumen Fund Announces Ripple Effect Pilot Projects In Kenya To Identify Innovative Solutions To Water Challenges 2Health News:Acumen Fund Announces Ripple Effect Pilot Projects In Kenya To Identify Innovative Solutions To Water Challenges 3Health News:Acumen Fund Announces Ripple Effect Pilot Projects In Kenya To Identify Innovative Solutions To Water Challenges 4Health News:Ageing Demographic Boosts Uptake of Wireless Patient Monitoring Devices Across Europe, Finds Frost & Sullivan 2Health News:Ageing Demographic Boosts Uptake of Wireless Patient Monitoring Devices Across Europe, Finds Frost & Sullivan 3Health News:Sentinelle Medical Introduces New Suite of Breast MRI Coils for GE, Siemens and Toshiba Scanners 2Health News:Sentinelle Medical Introduces New Suite of Breast MRI Coils for GE, Siemens and Toshiba Scanners 3Health News:Dr. Michael Aziz Releases a New Nutrition Book That Debunks Most Popular Diets and Diet Books 2Health News:Dr. Michael Aziz Releases a New Nutrition Book That Debunks Most Popular Diets and Diet Books 3Health News:Xybion Acquires Amadeus, a Leader in Governance, Risk, Compliance and Quality Management (GRC) Solutions 2Health News:Xybion Acquires Amadeus, a Leader in Governance, Risk, Compliance and Quality Management (GRC) Solutions 3
...d's loss to Argentina in a World Cup match in 1998...ttack rates by 27 per cent. The fact that extreme ...ulnerable people is known to almost everyone.Howev...e that hospital admissions for heart attack, stro...
...is received approval from the Food and Drug Admini...nkiller, which will be used to relieve post-operat...vartis facility at Puerto Rico //is the result of ...ties. The marketing campaign for the drug was...
... fish at least once a month can minimise the risk ...d researchers. Around 607 participants deve...w study involving more than 43,005 men aged 39 to ...ere confirmed as hemorrhagic stroke, caused by a l...
...chers at the Medical college of Wisconsin have rec...otective reflexes in the throat area. A one-way va...hroat and smoking causes damage to the// pharyngog...mokers were tested by imaging the relex area befor...
...ing to a recent study researchers have observed th...en though painful, is the best way forward in peri...hose aged 55// or over will be affected by periphe... this situation, you would think walking would be ...
... who are specialzed with specific skills do home c...sease. Chronic bronchitis and emphysema - or chron...ery disabling, because of breathlessness and impai...e home setting cuts costs, re-admission to hospita...
Other Medicine News:
(Date:12/1/2009)...c. 1 /PRNewswire-Asia-FirstCall/ -- Tianyin,Pharma...urer and supplier of,modernized traditional Chines...announced that it has received approvals from the ...to produce Pediatric Fever and Cough Oral Liquid i...Z20093060) and Antibacterial,and Anti-inflammatory...
(Date:12/1/2009)...ewswire-FirstCall/ -- Vanda Pharmaceuticals Inc. (...eriod has expired under the Hart-Scott-Rodino (HSR...to Vanda,s agreement, dated October 12, 2009, with... effective. Expiration of the waiting period, and...ggers an upfront payment to Vanda of $200 million....
(Date:12/1/2009)...wire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI )...oprietary antibodies for the treatment of cancer, ...ed that Bayer Schering Pharma AG has exercised its...e agreement entered into on January 12, 2009 to de...id tumors. ,, Under the terms of the agreement,...
Breaking Medicine Technology:Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA New Product Approvals for 2 Generic Products 2Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA New Product Approvals for 2 Generic Products 3Bayer Schering Exercises Option to Develop Solid Tumor BiTE Antibody with Micromet 2Bayer Schering Exercises Option to Develop Solid Tumor BiTE Antibody with Micromet 3Bayer Schering Exercises Option to Develop Solid Tumor BiTE Antibody with Micromet 4Red Cross Implements Change to Enhance Donor Safety for Younger Donors 59824 1Red Cross Implements Change to Enhance Donor Safety for Younger Donors 59824 2The Advisory Board Company Schedules Second Quarter Conference Call for November 2 2009 59822 1The Advisory Board Company Schedules Second Quarter Conference Call for November 2 2009 59822 2IntraHealth to Lead 24300 Million USAID Project in Global Health Workforce Systems Strengthening 59820 1IntraHealth to Lead 24300 Million USAID Project in Global Health Workforce Systems Strengthening 59820 2
...onstrated Sustained Improvement in Signs and,Sympt...h One-Third,of Patients Achieving Disease Remiss...007 – One-year data show nearly,75 percent o...ritis,(RA) receiving golimumab (CNTO 148) and meth... 20 percent improvement in,arthritis symptoms (ACR...
...ain, June 15, 2007 /PRNewswire-FirstCall/ --,Brist...garding the,efficacy and safety of ORENCIA(R) (aba...vestigational study in children with juvenile,idio...response to,one or more disease-modifying anti- rh... or tumor necrosis factor (TNF) antagonists.,The r...
Other Medicine Technology:Anti-TNF Golimumab Continues to Show Promise in Phase II Rheumatoid,Arthritis Study 2Anti-TNF Golimumab Continues to Show Promise in Phase II Rheumatoid,Arthritis Study 3Anti-TNF Golimumab Continues to Show Promise in Phase II Rheumatoid,Arthritis Study 4Anti-TNF Golimumab Continues to Show Promise in Phase II Rheumatoid,Arthritis Study 5Investigational Study Demonstrated a Re-Establishment of Clinical,Improvement with Orencia (Abatacept) in Children with Juvenile,Idiopathic Arthritis upon Re-Introduction of Therapy 2Investigational Study Demonstrated a Re-Establishment of Clinical,Improvement with Orencia (Abatacept) in Children with Juvenile,Idiopathic Arthritis upon Re-Introduction of Therapy 3Investigational Study Demonstrated a Re-Establishment of Clinical,Improvement with Orencia (Abatacept) in Children with Juvenile,Idiopathic Arthritis upon Re-Introduction of Therapy 4Investigational Study Demonstrated a Re-Establishment of Clinical,Improvement with Orencia (Abatacept) in Children with Juvenile,Idiopathic Arthritis upon Re-Introduction of Therapy 5Investigational Study Demonstrated a Re-Establishment of Clinical,Improvement with Orencia (Abatacept) in Children with Juvenile,Idiopathic Arthritis upon Re-Introduction of Therapy 6
...ies I Instrument program offers state-of-the-art q...while maintaining strength and durability. Low pro...ht joint spaces. Series I instruments are availabl...angle required for large and small joint arthrosco...
...ies I Instrument program offers state-of-the-art q...while maintaining strength and durability. Low pro...ht joint spaces. Series I instruments are availabl...angle required for large and small joint arthrosco...
...ies I Instrument program offers state-of-the-art q...while maintaining strength and durability. Low pro...ht joint spaces. Series I instruments are availabl...angle required for large and small joint arthrosco...
...ies I Instrument program offers state-of-the-art q...while maintaining strength and durability. Low pro...ht joint spaces. Series I instruments are availabl...angle required for large and small joint arthrosco...
Medicine Products: